HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Hairy Cell Leukemia Variant]]. | ||
Note: consider content on the overview page: Splenic B-cell Lymphoma/Leukemia, Unclassifiable | Note: consider content on the overview page: Splenic B-cell Lymphoma/Leukemia, Unclassifiable | ||
| Line 14: | Line 14: | ||
*Snehal Patel, MD, PhD | *Snehal Patel, MD, PhD | ||
==WHO Classification of Disease== | ==WHO Classification of Disease== | ||
| Line 38: | Line 37: | ||
|} | |} | ||
== | ==Related Terminology== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
|Acceptable | |Acceptable | ||
| | |Splenic B-cell lymphoma/leukaemia, unclassifiable | ||
|- | |- | ||
|Not Recommended | |Not Recommended | ||
| | |Hairy cell leukaemia variant; B-prolymphocytic leukaemia | ||
|} | |} | ||
| Line 242: | Line 111: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
*No consistent gene fusions | *No consistent gene fusions | ||
| Line 252: | Line 121: | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in: | ||
* Chromosomal Rearrangements (Gene Fusions) | * Chromosomal Rearrangements (Gene Fusions) | ||
* Individual Region Genomic Gain/Loss/LOH | * Individual Region Genomic Gain/Loss/LOH | ||
| Line 291: | Line 160: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Chr #!! | !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) | ||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||
| Line 341: | Line 210: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 366: | Line 235: | ||
!Chromosomal Pattern | !Chromosomal Pattern | ||
!Molecular Pathogenesis | !Molecular Pathogenesis | ||
! | !Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||
| Line 396: | Line 265: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
*Preferential utilization of IGHV4-34 (Immunoglobulin heavy chain variable segment) in 40%<ref>{{Cite journal|last=Xi|first=Liqiang|last2=Arons|first2=Evgeny|last3=Navarro|first3=Winnifred|last4=Calvo|first4=Katherine R.|last5=Stetler-Stevenson|first5=Maryalice|last6=Raffeld|first6=Mark|last7=Kreitman|first7=Robert J.|date=2012|title=Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation|url=https://ashpublications.org/blood/article/119/14/3330/29588/Both-variant-and-IGHV434expressing-hairy-cell|journal=Blood|language=en|volume=119|issue=14|pages=3330–3332|doi=10.1182/blood-2011-09-379339|issn=0006-4971|pmc=PMC3321859|pmid=22210875}}</ref> and has clinical implications<ref name=":4">{{Cite journal|last=Arons|first=Evgeny|last2=Suntum|first2=Tara|last3=Stetler-Stevenson|first3=Maryalice|last4=Kreitman|first4=Robert J.|date=2009|title=VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy|url=https://ashpublications.org/blood/article/114/21/4687/26430/VH434-hairy-cell-leukemia-a-new-variant-with-poor|journal=Blood|language=en|volume=114|issue=21|pages=4687–4695|doi=10.1182/blood-2009-01-201731|issn=0006-4971|pmc=PMC2780305|pmid=19745070}}</ref> | *Preferential utilization of IGHV4-34 (Immunoglobulin heavy chain variable segment) in 40%<ref>{{Cite journal|last=Xi|first=Liqiang|last2=Arons|first2=Evgeny|last3=Navarro|first3=Winnifred|last4=Calvo|first4=Katherine R.|last5=Stetler-Stevenson|first5=Maryalice|last6=Raffeld|first6=Mark|last7=Kreitman|first7=Robert J.|date=2012|title=Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation|url=https://ashpublications.org/blood/article/119/14/3330/29588/Both-variant-and-IGHV434expressing-hairy-cell|journal=Blood|language=en|volume=119|issue=14|pages=3330–3332|doi=10.1182/blood-2011-09-379339|issn=0006-4971|pmc=PMC3321859|pmid=22210875}}</ref> and has clinical implications<ref name=":4">{{Cite journal|last=Arons|first=Evgeny|last2=Suntum|first2=Tara|last3=Stetler-Stevenson|first3=Maryalice|last4=Kreitman|first4=Robert J.|date=2009|title=VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy|url=https://ashpublications.org/blood/article/114/21/4687/26430/VH434-hairy-cell-leukemia-a-new-variant-with-poor|journal=Blood|language=en|volume=114|issue=21|pages=4687–4695|doi=10.1182/blood-2009-01-201731|issn=0006-4971|pmc=PMC2780305|pmid=19745070}}</ref> | ||
| Line 410: | Line 279: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene!! | !Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span>''EGFR'' | |<span class="blue-text">EXAMPLE:</span>''EGFR'' | ||
| Line 452: | Line 321: | ||
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 536: | Line 405: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
{| class="wikitable" | {| class="wikitable" | ||
!Molecular feature | !Molecular feature | ||
| Line 584: | Line 453: | ||
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | ||
<br /> | |||
==Notes== | ==Notes== | ||
| Line 593: | Line 462: | ||
<nowiki>*</nowiki>''Citation of this Page'': “Splenic B-cell lymphoma/leukaemia with prominent nucleoli”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Splenic_B-cell_lymphoma/leukaemia_with_prominent_nucleoli</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': “Splenic B-cell lymphoma/leukaemia with prominent nucleoli”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Splenic_B-cell_lymphoma/leukaemia_with_prominent_nucleoli</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases S]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases S]] | |||